D1 dopamine receptor agonists are more effective in alleviating advanced than mild Parkinsonism in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 292, Issue 2, 2000, Pages 714-724

  Goulet, Martin ^a   Madras, Bertha K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 PROPYL 9 HYDROXY 2,3,4ALPHA,5,6,10BETA HEXAHYDRO 4H NAPHTH[1,2 B][1,4]OXAZINE; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; DIHYDREXIDINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; QUINELORANE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DYSKINESIA; FEMALE; MALE; MONKEY; NEUROPHARMACOLOGY; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BEHAVIOR, ANIMAL; BENZAZEPINES; DOPAMINE AGENTS; DOPAMINE AGONISTS; DYSKINESIA, DRUG-INDUCED; FEMALE; MACACA FASCICULARIS; MALE; MOTOR ACTIVITY; MOTOR SKILLS; OXAZINES; PARKINSONIAN DISORDERS; PHENANTHRIDINES; QUINOLINES; RECEPTORS, DOPAMINE D1;

EID: 0033980790     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Andringa G, Vermeulen RJ, Drukarch B, Stoof JC and Cools AS (1998) Dopamine receptor subtypes as targets for the pharmacotherapy of Parkinson's disease. Adv Pharmacol 42:792-795.
2. Asin KE, Domino EF, Nikkel A and Shiosaki K (1997) The selective dopamine D1 receptor agonist A-86929 maintains efficacy with repeated treatment in rodent and primate models of Parkinson's disease. J Pharmacol Exp Ther 281:454-459.
3. 1 receptor stimulation in normal and MPTP monkeys. Neurosci Lett 104:223-228.
4. 2 agonists in inducing dyskinesia in drug-naive MPTP monkeys. Adv Neurol 60:113-118.
5. Bergamasco B, Benna P and Scarzella L (1990) Long-term bromocriptine treatment of de novo patients with Parkinson's disease: A seven-year follow-up. Acta Neurol Scand 81:383-387.
6. Blanchet P, Bedard PJ, Britton DR and Kebabian JW (1993) Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri. J Pharmacol Exp Ther 267:275-279.
7. Blanchet PJ, Fang J, Gillespie M, Sabounjian L, Locke KW, Gammans R, Mouradian MM and Chase TN (1998) Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease. Clin Neuropharmacol 21:339-343.
8. Blanchet PJ, Grondin R and Bedard PJ (1996a) Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. Mov Disord 11:91-94.
9. Blanchet PJ, Grondin R, Bedard PJ, Shiosaki K and Britton DR (1996b) Dopamine D1 receptor desensitization profile in MPTP-lesioned primates. Eur J Pharmacol 309:13-20.
10. Bonnet AM, Loria Y, Saint-Hilaire MH, Lhermitte F and Agid Y (1987) Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions? Neurology 37:1539-1542.
11. Boyce S, Rupniak NM, Steventon MJ and Iversen SD (1990) Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys. Clin Neuropharmacol 13:448-458.
12. Braun A, Fabbrini G, Mouradian MM, Serrati C, Barone P and Chase TN (1987) Selective D-1 dopamine receptor agonist treatment of Parkinson's disease. J Neural Transm 68:41-50.
13. Domino EF and Sheng J (1993) Relative potency and efficacy of some dopamine agonists with varying selectivities for D1 and D2 receptors in MPTP-induced hemiparkinsonian monkeys [published erratum appears in J Pharmacol Exp Ther 1993 267:566]. J Pharmacol Exp Ther 265:1387-1391.
14. Dracheva S, Xu M, Kelley KA, Haroutunian V, Holstein GR, Haun S, Silverstein JH and Sealfon SC (1999) Paradoxical locomotor behavior of dopamine D1 receptor transgenic mice. Exp Neurol 157:169-179.
15. Eidelberg E, Brooks BA, Morgan WW, Walden JG and Kokemoor RH (1986) Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys. Neuroscience 18:817-822.
16. Fahn S, Elton RL and Members of the UPDRS Development Committee (1987) Unified Parkinson's Disease Rating Scale, in Recent Developments in Parkinson's Disease (Fahn ed) pp 153-160, Macmillan Health Care Information, Florham Park, NJ.
17. Gottwald MD, Bainbridge JL, Dowling GA, Aminoff MJ and Alldredge BK (1997) New pharmacotherapy for Parkinson's disease. Ann Pharmacother 31:1205-1217.
18. Goulet M, Grondin R, Blanchet PJ, Bedard PJ and Di Paolo T (1996) Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys. Brain Res 719:129-137.
19. Goulet M and Madras BK (1998) Efficacy of a dopamine D1 receptor agonist depends on severity of parkinsonism. Soc Neurosci Abstr 24:303.3.
20. Grondin R, Bedard PJ, Britton DR and Shiosaki K (1997) Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: An acute study in parkinsonian levodopa-primed monkeys. Neurology 49:421-426.
21. Hantraye P, Varastet M, Peschanski M, Riche D, Cesaro P, Willer JC and Maziere M (1993) Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons. Neuroscience 53:169-178.
22. Hoehn MM and Yahr MD (1967) Parkinsonism: Onset, progression and mortality. Neurology 17:427-442.
23. Kurlan R, Kim MH and Gash DM (1991) The time course and magnitude of spontaneous recovery of parkinsonism produced by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys. Ann Neurol 29:677-679.
24. Lovenberg TW, Brewster WK, Mottola DM, Lee RC, Riggs RM, Nichols DE, Lewis MH and Mailman RB (1989) Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist. Eur J Pharmacol 166:111-113.
25. Luquin MR, Guillen J, Martinez-Vila E, Laguna J and Martinez-Lage JM (1994) Functional interaction between dopamine D1 and D2 receptors in "MPTP" monkeys. Eur J Pharmacol 253:215-224.
26. Madras BK (1993) Dopamine and D1 dopamine receptor agonists; Dopamine receptor selectivity and response to guanine nucleotides in nonhuman primate brain. Soc Neurosci Abstr 19:1063.
27. Marsden CD and Parkes JD (1977) Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1:345-349.
28. Mottola DM, Brewster WK, Cook LL, Nichols DE and Mailman RB (1992) Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist. J Pharmacol Exp Ther 262:383-393.
29. Neve KA and Neve RL (1997) Molecular biology of dopamine receptors, in The Dopamine Receptors (Neve KA and Neve RL eds) pp 27-76, Humana Press, Totowa, NJ.
30. Pifl C, Reither H and Hornykiewicz O (1991) Lower efficacy of the dopamine D1 agonist, SKF 38393, to stimulate adenylyl cyclase activity in primate than in rodent striatum. Eur J Pharmacol 202:273-276.
31. 3H]SCH 23390 to D-1 receptors in the putamen of control and parkinsonian subjects. Eur J Pharmacol 113:467-468.
32. Rascol O, Blin O, Thalamas C, Descombes S, Soubrouillard C, Azulay P, Fabre N, Viallet F, Lafnitzegger K, Wright S, Carter JH and Nutt JG (1999) ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease. Ann Neurol 45:736-741.
33. Rascol O, Brooks DJ, Brunt ER, Korczyn AD, Poewe WH and Stocchi F (1998) Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study: 056 Study Group. Mov Disord 13:39-45.
34. Rinne JO, Laihinen A, Lonnberg P, Marjamaki P and Rinne UK (1991) A postmortem study on striatal dopamine receptors in Parkinson's disease. Brain Res 556:117-122.
35. Rupniak NM, Tye SJ, Jennings CA, Loper AE, Bondi JV, Hichens M, Hand E, Iversen SD and Stahl SM (1989) Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys. Neurology 39:329-335.
36. Schneider JS, Sun ZQ and Roeltgen DP (1994) Effects of dihydrexidine, a full dopamine D-1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys. Brain Res 663:140-144.
37. Shiosaki K, Jenner P, Asin KE, Britton DE, Lin CW, Michaelides M, Smith L, Bianchi B, Didomenico S, Hodges L, Hong Y, Mahan L, Mikusa J, Miller T, Nikkel A, Stashko M, Witte D and Williams M (1996) ABT-431: The diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease. J Phamacol Exp Ther 276:150-160.
38. Taylor JR, Lawrence MS, Redmond DE Jr, Elsworth JD, Roth RH, Nichols DE and Mailman RB (1991) Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys. Eur J Pharmacol 199:389-391.
39. Temlett JA, Quinn NP, Jenner PG, Marsden CD, Pourcher E, Bonnet AM, Agid Y, Markstein R and Lataste X (1989) Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease. Mov Disord 4:261-265.
40. Tetrud JW and Langston JW (1992) Tremor in MPTP-induced parkinsonism. Neurology 42:407-410.
41. Vermeulen RJ, Drukarch B, Sahadat MC, Goosen C, Wolters EC and Stoof JC (1993) The selective dopamine D1 receptor agonist, SKF 81297, stimulates motor behaviour of MPTP-lesioned monkeys. Eur J Pharmacol 235:143-147.